Reassessing heart failure therapy in Thailand: Patient insights and treatment outcomes from the Thai heart failure registry
Issued Date
2024-09-01
Resource Type
ISSN
01675273
eISSN
18741754
Scopus ID
2-s2.0-85195314810
Journal Title
International Journal of Cardiology
Volume
410
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Cardiology Vol.410 (2024)
Suggested Citation
Krittayaphong R., Yingchoncharoen T., Puwanant S., Boonyapiphat T., Charoenyos N., Wongtheptien W., Chotenimitkhun R., Chichareon P., Phrommintikul A., Thundee C., Chirakarnjanakorn S., Ariyachaipanich A., Senthong V., Kanjanavanich R., Buakhamsri A., Chantrarat T., Ratanasumawong K., Songmuang S.B., Sethalao P., Kunjara-Na-Ayudhya R. Reassessing heart failure therapy in Thailand: Patient insights and treatment outcomes from the Thai heart failure registry. International Journal of Cardiology Vol.410 (2024). doi:10.1016/j.ijcard.2024.132235 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/98732
Title
Reassessing heart failure therapy in Thailand: Patient insights and treatment outcomes from the Thai heart failure registry
Author(s)
Krittayaphong R.
Yingchoncharoen T.
Puwanant S.
Boonyapiphat T.
Charoenyos N.
Wongtheptien W.
Chotenimitkhun R.
Chichareon P.
Phrommintikul A.
Thundee C.
Chirakarnjanakorn S.
Ariyachaipanich A.
Senthong V.
Kanjanavanich R.
Buakhamsri A.
Chantrarat T.
Ratanasumawong K.
Songmuang S.B.
Sethalao P.
Kunjara-Na-Ayudhya R.
Yingchoncharoen T.
Puwanant S.
Boonyapiphat T.
Charoenyos N.
Wongtheptien W.
Chotenimitkhun R.
Chichareon P.
Phrommintikul A.
Thundee C.
Chirakarnjanakorn S.
Ariyachaipanich A.
Senthong V.
Kanjanavanich R.
Buakhamsri A.
Chantrarat T.
Ratanasumawong K.
Songmuang S.B.
Sethalao P.
Kunjara-Na-Ayudhya R.
Author's Affiliation
Ramathibodi Hospital
Siriraj Hospital
Faculty of Medicine, Chiang Mai University
Lampang Hospital
Faculty of Medicine, Khon Kaen University
Faculty of Medicine, Prince of Songkla University
Police General Hospital
Surin Hospital
Faculty of Medicine, Thammasat University
Vichaiyut Hospital
Phramongkutklao College of Medicine
Faculty of Medicine, Chulalongkorn University
Chaophraya Yommarat Hospital
Chiangrai Prachanukroh Hospital
Siriraj Hospital
Faculty of Medicine, Chiang Mai University
Lampang Hospital
Faculty of Medicine, Khon Kaen University
Faculty of Medicine, Prince of Songkla University
Police General Hospital
Surin Hospital
Faculty of Medicine, Thammasat University
Vichaiyut Hospital
Phramongkutklao College of Medicine
Faculty of Medicine, Chulalongkorn University
Chaophraya Yommarat Hospital
Chiangrai Prachanukroh Hospital
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: This research analyzed the demographics, management, and outcomes of patients with heart failure (HF) in Thailand. Methods: The Thai Heart Failure Registry prospectively enrolled patients diagnosed with HF from 36 hospitals in Thailand. Follow-up data were recorded at 6, 12, 18, and 24 months. This study primarily focused on two outcomes: mortality and HF-related hospitalizations. Results: The study included 2639 patients aged at least 18. Their mean age was 59.2 ± 14.5 years, and most were male (68.4%). Patients were classified as having HF with reduced ejection fraction (HFrEF, 80.7%), HF with preserved ejection fraction (HFpEF, 9.0%), or HF with mildly reduced ejection fraction (HFmrEF, 10.3%). Guideline-directed medical therapy utilization varied. Beta-blockers had the highest usage (93.2%), followed by mineralocorticoid receptor antagonists (65.7%), angiotensin-converting enzyme inhibitors (39.3%), angiotensin receptor blockers (28.2%), angiotensin receptor-neprilysin inhibitors (16.1%), and sodium-glucose cotransporter-2 inhibitors (8.0%). The study monitored a composite of mortality and HF incidents, revealing incidence rates of 11.74, 12.50, and 8.93 per 100 person-years for the overall, HFrEF, and HFmrEF/HFpEF populations, respectively. Conclusions: Despite high guideline-directed medical therapy adherence, the Thai Heart Failure Registry data revealed high mortality and recurrent HF rates. These findings underscore limitations in current HF treatment efficacy. The results indicate the need for further investigation and improvements of HF management to enhance patient outcomes.